SAN
DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology
company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr.
Kaseta has an extensive background spanning corporate finance,
business strategy, and the commercialization of biopharma products
in large pharmaceutical companies and small biotech companies.
Mr. Kaseta currently serves as the Chief Financial Officer and
Chief Operating Officer of Liquidia Corporation, a
biopharmaceutical company developing innovative therapies for
patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr.
Kaseta served as the Chief Financial Officer at Aerami
Therapeutics, Inc., a private biotech company focused on the
development of improved therapies for the treatment of severe
respiratory diseases, including pulmonary arterial hypertension.
Previously, Mr. Kaseta served as the Chief Financial Officer at
Aralez Pharmaceuticals, Inc., and spent eleven years at Sanofi
S.A. in a variety of financial roles, culminating in the Chief
Financial Officer role at Sanofi North America, Global Services. In
this role he managed a $10 billion
business covering several product launches and more than 100
products across eight therapeutic areas. Mr. Kaseta holds a BBA in
accounting from James Madison
University, is a CPA (inactive) licensed in the state of
New Jersey, and serves as a
director of Bryn Pharma.
"We are excited to welcome Mike and his deep experience in
commercial biotechnology leadership to Heron's Board of Directors,"
said Craig Collard, Chief Executive
Officer of Heron. "I look forward to working with Mike more closely
and I am confident that he will be an important asset to the Board
as we drive continued growth of our existing portfolio of
proprietary products focused on improving the lives of
patients."
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology
company focused on improving the lives of patients by developing
and commercializing therapeutic innovations that improve medical
care. Our advanced science, patented technologies, and innovative
approach to drug discovery and development have allowed us to
create and commercialize a portfolio of products that aim to
advance the standard-of-care for acute care and oncology patients.
For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the company's filings with the
Securities and Exchange Commission. Forward-looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-michael-kaseta-to-board-of-directors-302295904.html
SOURCE Heron Therapeutics, Inc.